BioCentury
ARTICLE | Company News

Harvard Pilgrim, Lilly partner on Trulicity outcomes

June 29, 2016 1:43 AM UTC

Under a deal with regional payer Harvard Pilgrim Health Care Inc. (Boston, Mass.), the reimbursement and rebate amount for diabetes drug Trulicity dulaglutide from Eli Lilly and Co. (NYSE:LLY) will hinge on how well the drug lowers HbA1c relative to others in its class.

Lilly agreed to an undisclosed rebate to gain access to Harvard Pilgrim's preferred formulary. The rebate's size may rise or fall depending upon the proportion of Harvard Pilgrim participants who take Trulicity and achieve an HbA1c of 8%. If the target is met by a higher percentage of patients receiving Trulicity than by patients on other analogs of glucagon-like peptide-1 (GLP-1), the rebate shrinks. If a lower percentage of patients on Trulicity meets the target, the rebate grows. ...